跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 49,788 条关于
“NRG1 fusion-positive tumors”
全部
49,788
临床试验
34,742
药物
1,058
机构
139
资讯
13,849
去年
Zenocutuzumab Achieves 30% Response Rate in NRG1 Fusion-Positive Solid Tumors, Receives FDA Approval
去年
Merus' Bizengri Receives FDA Approval for NRG1 Fusion-Positive Cancers
去年
FDA Extends Review of Zenocutuzumab for NRG1 Fusion-Positive Cancers
去年
Novocure's Device Shows Promise in Pancreatic Cancer, FDA Reviews Cytokinetics' Heart Drug
去年
FDA Approves Bizengri for NRG1 Fusion-Positive Lung and Pancreatic Cancers
11个月前
Zenocutuzumab Shows 37% Response Rate in Rare NRG1-Positive Cholangiocarcinoma
4个月前
Chugai's Alecensa Receives World's First Tumor-Agnostic Approval for ALK Fusion-Positive Solid Tumors
去年
FDA Approves First Systemic Therapy for NRG1 Fusion-Positive Cancers and MSC Therapy for SR-aGVHD
9个月前
Zenocutuzumab Shows Superior Efficacy in Treatment-Naïve NRG1+ NSCLC Patients
3个月前
Vcare PharmaTech's Next-Generation TRK Inhibitor Eratrectinib Wins NMPA Approval for NTRK Fusion-Positive Solid Tumors
第 1 页，共 1385 页
上一页
下一页
